Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, (90)Y-DOTATATE, and LAR octreotide analogue): a case report.
Carcinoids are the most common neuroendocrine tumours. They are usually slowly growing, located in the small intestine, secrete serotonin, and are characterized by long survival of patients, so prognosis is generally good. The most frequently encountered clinical presentations of carcinoids are intermittent abdominal pain and carcinoid syndrome (diarrhoea and flushing). Metastases worsen the prognosis and limit the survival of the patients. We report a case of carcinoid tumour with primary focus in the ileum, with an appendix infiltration, in a thirty-two-year-old woman with acute appendicitis symptoms only. Carcinoid was diagnosed postoperatively by histopathological examination. Nowadays, twenty-five years after the surgery, there is evidence of nearly asymptomatic numerous metastases. Only intermittent abdominal pain for about 1-2 years was reported. Partial metastases resection was performed, followed by chemotherapy, (90)Y-DOTATATE and then long-acting release octreotide analogue therapy. In the meantime, severe chronic heart failure (NYHA IV) due to tricuspid combined valvular heart disease and pulmonary hypertension was diagnosed. Combined therapy, typical for chronic heart failure, together with long-acting octreotide analogue highly improved the patient's heart sufficiency and reduced carcinoid syndrome symptoms. The only adverse events of octreotide therapy were hyperbilirubinaemia and itching. Long-term survival is typical for carcinoids, but 30-years survival has not been described in the literature yet.
Kałuzny
Marcin
M
Department of Endocrinology, Diabetology and Isotope Therapy, Medical University, Wroclaw. mkaluzny@poczta.onet.pl
Bolanowski
Marek
M
Sukiennik-Kujawa
Małgorzata
M
Ponikowski
Piotr
P
Handkiewicz-Junak
Daria
D
Jarzab
Barbara
B
Jawiarczyk
Aleksandra
A
Syrycka
Joanna
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002275:Carcinoid Heart Disease / Q000175:diagnosis / Q000628:therapy; D002276:Carcinoid Tumor / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D007078:Ileal Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage; D017741:Survivors
D004317:Doxorubicin; D003520:Cyclophosphamide; D015282:Octreotide; D005472:Fluorouracil